July 14, 2021 10:57 AM EDT

Trial software group raises $45M to push decentralized studies; $120M SPAC makes its way to Nasdaq

John Carroll

Editor & Founder

Max Gelman

Senior Editor

After watching the entire clinical trial process go through a major makeover during the pandemic, another software outfit is making a play to help developers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Trial software group raises $45M to push decentralized studies; $120M SPAC makes its way to Nasdaq

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Tri­al soft­ware group rais­es $45M to push de­cen­tral­ized stud­ies; $120M SPAC makes its way to Nas­daq

Editor & Founder

Senior Editor

Sign up to read this article for free.

Trial software group raises $45M to push decentralized studies; $120M SPAC makes its way to Nasdaq